系统性炎症调节慢性冠状动脉综合征中的脂蛋白相关冠状动脉狭窄
Lu Shen1,2, Wenqing Zhai1, Ping Jiang3
1Department of Health Promotion and Behavioural Sciences, School of Public Health, Anhui Medical University, No.69 Meishan Road, Shushan District, Hefei, Anhui Province, China.
American journal of preventive cardiology
|October 27, 2025
概括
升高的脂蛋白 (a) [Lp (a) ]会增加冠状动脉狭窄的风险,但只有当全身炎症较低时. 慢性冠状动脉综合征 (CCS) 的个性化疗法应考虑炎症水平,以有效管理Lp.
科学领域:
- 心脏病学 心脏病学
- 炎症研究 炎症研究
- 血管生物学 血管生物学
背景情况:
- 脂蛋白[Lp[a]水平和相关的心血管风险与全身炎症有关.
- 研究系统性炎症在慢性冠状动脉综合征 (CCS) 中调节Lp(a) 相关冠状动脉狭窄的作用至关重要.
研究的目的:
- 确定系统性炎症是否影响慢性冠状动脉综合征患者中脂蛋白和冠状动脉狭窄严重程度之间的关系.
- 探索不同程度的炎症对与Lp (a) 相关的冠状动脉疾病风险的影响.
主要方法:
- 一项对1513名接受冠状动脉血管造影的患者进行了回顾性,横截面研究.
- 患者根据冠状动脉狭窄的严重程度进行了分层,使用Gensini评分,并根据系统性炎症水平 (SIRI,SII,NLR) 分类.
- 用多项逻辑回归模型分析了不同炎症条件下的Lp (a) 和狭窄之间的关联.
主要成果:
- 在整体队列中,升高的Lp (a) 与冠状动脉狭窄风险 (轻度和重度) 的增加显著相关.
- 这种关联在患有低系统性炎症 (SIRI <0.64) 的患者中最为明显,轻度和重度狭窄的几率显著更高.
- 在中度或高系统性炎症患者中,没有观察到Lp(a) 和冠状动脉狭窄之间的显着关联.
结论:
- 升高脂蛋白和冠状动脉狭窄之间的相关性取决于低系统性炎症水平.
- 针对慢性冠状动脉综合征的个性化治疗策略应包括对患者炎症状况的评估,以实现最佳管理.
相关概念视频
01:38Inflammation
61.6K
Overview
61.6K
01:26Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
01:26Coronary Artery Disease II: Pathophysiology
360
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
360
01:30Coronary Artery Disease I: Introduction
869
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
869
01:30Atherosclerosis I: Introduction
890
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
890
01:30Coronary Artery Disease III: Clinical Manifestations
317
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
317